USPTO 2015–2025 USPTO PatentsView US Corporation

Athena Diagnostics, Inc.

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, active 2017–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

7
Total patents granted
3
CPC technology areas
11.4
Avg claims per patent
+150%
5-year filing velocity

The verdict

Athena holds 7 US patents across 3 technology areas, rank #34,364 of 50,000 tracked assignees.

#34,364
of 50,000 US assignees by volume
Top 88%
by Innovation Score (23.5/100)
11.4
avg claims per patent
+150%
filing velocity, last 5 yrs

Portfolio overview

Athena Diagnostics, Inc. has been granted 7 US utility patents between 2017 and 2023, placing Athena Diagnostics, Inc. at rank #34,364 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.4 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Athena Diagnostics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Athena sits between Asha Medical, Inc. (7 patents, rank #34,360) and Atkore Steel Components, Inc. (7 patents, rank #34,368) - the closest US assignees by grant volume. The composite Innovation Score of 23.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 2 in the 2015–2019 window, a +150% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Athena Diagnostics, Inc.'s 11.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Athena Diagnostics, Inc. against peers pursuing similar technology classes.

Who files at Athena's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Athena holds 7 patents at rank #34,364, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Athena

By rank, the assignees closest to #34,364 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Athena's primary technology class.

Athena's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

24 Top 88% higher than 12% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). This entry sits in this band. 30–40: 15,294 US assignees (31%). Above this entry. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.533.5 20172019202020222023 1
USPTO utility patent grants by year · 2017–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Athena Diagnostics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 14.3%
2019 1 14.3%
2020 3 42.9%
2022 1 14.3%
2023 1 14.3%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Velocity Accelerating

Where it ranks

Overall rank by patents

#34,364

Across all tracked assignees

Innovation Score

23.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Athena Diagnostics, Inc. hold?
Athena Diagnostics, Inc. holds 7 US granted patents filed between 2017 and 2023, spanning 3 technology areas.
What is Athena Diagnostics, Inc.'s Innovation Score?
Athena Diagnostics, Inc. has an Innovation Score of 23.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Athena Diagnostics, Inc. focus on?
Athena Diagnostics, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 6 patents. The company has filed patents in 3 CPC subclasses total.
Is Athena Diagnostics, Inc.'s patent filing rate increasing or decreasing?
Athena Diagnostics, Inc.'s recent filing velocity is +150% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Athena Diagnostics, Inc.'s patents?
Athena Diagnostics, Inc.'s patents average 11.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Athena Diagnostics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Athena's 7 grants land it in the top 88% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Athena ranks #34,364 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.